# DESCRIPTION

## TECHNICAL FIELD

- define technical field

## BACKGROUND

- describe allergic diseases
- discuss IgE and omalizumab

## SUMMARY

- introduce omalizumab-resistant IgE variants
- describe composition and method of use
- outline therapeutic applications

## DETAILED DESCRIPTION

- introduce background and scope of the invention

### I. DEFINITIONS

- define terms used in the specification
- explain singular forms and plural referents
- define "about" in reference to a given quantity
- define "polypeptide" and "protein"
- define IgE polynucleotide, nucleic acid, oligonucleotide, protein, polypeptide, or peptide
- define "variant," "analog," and "mutein"
- define "derivative"
- define "fragment"
- define "substantially purified" and "isolated"

### II. MODES OF CARRYING OUT THE INVENTION

- clarify scope of invention
- introduce omalizumab-resistant IgE variant therapy
- describe design of omalizumab-resistant IgE variants
- discuss production of omalizumab-resistant IgE variants
- outline pharmaceutical compositions of omalizumab-resistant IgE variants
- detail excipients and additives for pharmaceutical compositions
- list excipients
- describe composition preparation
- outline administration methods
- detail dosing regimens
- describe concurrent therapy
- outline kit composition
- describe kit contents

### III. EXPERIMENTAL

- introduce example 1
- describe structural basis of omalizumab therapy
- present results of structure of IgE-omalizumab complex
- analyze impact of IgE-Fc conformation on omalizumab binding
- discuss binding kinetics of omalizumab with IgE variants
- analyze kinetic data
- establish omalizumab epitope
- describe structural basis of FcεRI and CD23 competition
- calculate steric overlap and inhibitor-induced FcεRIα complex dissociation
- compare omalizumab and E2_79 binding sites and steric conflicts
- validate observations with IgE-Fc3-4 mutant
- explore exchange of IgE on human basophils
- describe experimental design
- perform IgE reloading and tracking
- analyze omalizumab treatment effects
- discuss IgE-R419N-Fc3-4 and omalizumab synergy
- outline potential therapeutic applications
- detail methods for protein preparation and crystallization
- determine crystal structure of IgE:omalizumab complex
- calculate volume overlaps of IgE-binding molecules
- perform biotinylation and basophil IgE exchange experiments
- conduct SPR assays and functional assays with primary human basophils

